Literature DB >> 21254069

Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys.

Katsuaki Ito1, Yasuo Uchida, Sumio Ohtsuki, Sanshiro Aizawa, Hirotaka Kawakami, Yuki Katsukura, Junichi Kamiie, Tetsuya Terasaki.   

Abstract

Cynomolgus monkey has been used as a model for the prediction of drug disposition in human brain. The purpose of this study was to clarify protein expression levels of membrane proteins affecting drug distribution to brain, such as transporters, receptors, and junctional proteins, in cynomolgus monkey brain microvessels by using liquid chromatography tandem mass spectrometry. In adult monkeys, three ATP-binding cassette transporters (multidrug resistance 1 (MDR1), breast cancer resistance protein (BCRP), and multidrug resistance protein 4 (MRP4)), six solute carrier transporters (glucose transporter 1 (GLUT1), GLUT3/14, monocarboxylate transporter 1 (MCT1), MCT8, organic anion transporting polypeptide 1A2, and equilibrative nucleoside transporter 1), two junctional proteins (claudin-5 and vascular endothelial cadherin), and two receptors (insulin receptor and low-density lipoprotein receptor-related protein 1) were detected. Comparison of the expression levels with those in mouse, which we reported previously, revealed a pronounced species difference. BCRP expression in monkey was greater by 3.52-fold than that in mouse, whereas MDR1 and MRP4 expression levels in monkey were lower by 0.304- and 0.180-fold, respectively, than that in mouse. This study also investigated the developmental changes in expression of membrane proteins in neonate and child monkeys. Expression of MDR1 was similar in neonate and adult monkeys, whereas in rat, P-glycoprotein expression was reported to be significantly lower in brain microvessels of neonate as compared with adult rat. These results will be helpful to understand and predict brain concentrations of drugs in different species and at different ages of primates.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21254069     DOI: 10.1002/jps.22487

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  62 in total

Review 1.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

Review 2.  Stable isotope dilution mass spectrometry for membrane transporter quantitation.

Authors:  Vahid Farrokhi; Adam J McShane; Reza Nemati; Xudong Yao
Journal:  AAPS J       Date:  2013-10       Impact factor: 4.009

3.  Oxidative stress-induced activation of Abl and Src kinases rapidly induces P-glycoprotein internalization via phosphorylation of caveolin-1 on tyrosine-14, decreasing cortisol efflux at the blood-brain barrier.

Authors:  Yutaro Hoshi; Yasuo Uchida; Masanori Tachikawa; Sumio Ohtsuki; Pierre-Olivier Couraud; Takashi Suzuki; Tetsuya Terasaki
Journal:  J Cereb Blood Flow Metab       Date:  2019-01-09       Impact factor: 6.200

4.  The Inhibitor Ko143 Is Not Specific for ABCG2.

Authors:  Lora D Weidner; Sami S Zoghbi; Shuiyu Lu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Jan Mulder; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  J Pharmacol Exp Ther       Date:  2015-07-06       Impact factor: 4.030

Review 5.  SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers.

Authors:  Marilyn E Morris; Vivian Rodriguez-Cruz; Melanie A Felmlee
Journal:  AAPS J       Date:  2017-06-29       Impact factor: 4.009

Review 6.  Quantitative targeted proteomics for membrane transporter proteins: method and application.

Authors:  Xi Qiu; Hui Zhang; Yurong Lai
Journal:  AAPS J       Date:  2014-05-15       Impact factor: 4.009

Review 7.  β-Hydroxybutyrate in the Brain: One Molecule, Multiple Mechanisms.

Authors:  Lavanya B Achanta; Caroline D Rae
Journal:  Neurochem Res       Date:  2016-11-08       Impact factor: 3.996

Review 8.  Solute Carriers in the Blood-Brain Barier: Safety in Abundance.

Authors:  Katarzyna A Nałęcz
Journal:  Neurochem Res       Date:  2016-08-09       Impact factor: 3.996

9.  Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.

Authors:  Nicolas Tournier; Sebastien Goutal; Severin Mairinger; Irene Hernández-Lozano; Thomas Filip; Michael Sauberer; Fabien Caillé; Louise Breuil; Johann Stanek; Anna F Freeman; Gaia Novarino; Charles Truillet; Thomas Wanek; Oliver Langer
Journal:  J Cereb Blood Flow Metab       Date:  2020-10-20       Impact factor: 6.200

10.  Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.

Authors:  Fredrik Jeppsson; Susanna Eketjäll; Juliette Janson; Sofia Karlström; Susanne Gustavsson; Lise-Lotte Olsson; Ann-Cathrine Radesäter; Bart Ploeger; Gvido Cebers; Karin Kolmodin; Britt-Marie Swahn; Stefan von Berg; Tjerk Bueters; Johanna Fälting
Journal:  J Biol Chem       Date:  2012-10-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.